# CAMBRIA-2 (NCT05952557)

> An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05952557
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Breast Cancer, Early Breast Cancer
- Interventions: Camizestrant; Tamoxifen; Anastrozole; Letrozole; Exemestane; Abemaciclib
- Enrollment: 5511
- Primary outcome: Invasive breast cancer-free survival (IBCFS)

## Commentary we found

- YouTube: 33
- Podcasts: 17
- X threads: 9

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=cambria-2-nct05952557

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05952557", "email": "<work email>"}; the inbox owner confirms by the emailed link.